Ethical transparency and economic medicalization

Journal of Business Ethics

Volumn 86, Issue 3, 2009, Pages 313-325

  Poitras, Geoffrey ^a   Meredith, Lindsay ^a  

^a SIMON FRASER UNIVERSITY   (Canada)

Author keywords

Bioethics; Medical ethics; Medicalization; Shareholder wealth maximization

Indexed keywords

EID: 67349250739     PISSN: 01674544     EISSN: 15730697     Source Type: Journal    
DOI: 10.1007/s10551-008-9849-2     Document Type: Article

References (49)

1. American Medical Association: (2006). Code of Medical Ethics of the American Medical Association, Current Opinions with Annotations 2006-2007, Chicago, IL: American Medical Association
2. M. Andersen J. Kragstrup J. Sondergaard 2006 How Conducting a Clinical Trial Affects Physicians' Guideline Adherence and Drug Preferences Journal of the American Medical Association 295 June 2759 2764 10.1001/jama.295.23.2759 (Pubitemid 43920729)
3. Angell M.: (2004). The Truth About Drug Companies: How They Deceive Us and What to do About It. New York: Random House
4. J. Avorn 2006 "Dangerous Deception" Hiding the Evidence of Adverse Drug Effects The New England Journal of Medicine 355 November 2169 2171 10.1056/NEJMp068246
5. C. Berg K. Fryer-Edwards 2008 The Ethical Challenges of Direct-to-Consumer Genetic Testing Journal of Business Ethics 77 17 31 10.1007/s10551-006-9298-8
6. L. Bero D. Rennie 1996 Influences on the Quality of Published Drug Studies International Journal of Technology Assessment in Health Care 12 209 237 (Pubitemid 26195521)
7. M. Bhandari J. Busse D. Jackowski V. Montori H. Schünemann S. Sprague 2004 Association Between Industry Funding and Statistically Significant Pro-Industry Findings in Medical and Surgical Randomized Trials Canadian Medical Association Journal 170 477 480 (Pubitemid 38293642)
8. E. Campbell 2007 Doctors and Drug Companies: Scrutinizing Influential Relationships The New England Journal of Medicine 357 November 1796 1797 10.1056/NEJMp078141 (Pubitemid 350044799)
9. Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada, Social Sciences and Humanities Research Council of Canada: 1998, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. 1998 (with 2000, 2002, 2005 Amendments)
10. Caplovitz, A.: 2006, 'Turning Medicine into Snake Oil: How Pharmaceutical Marketers Put Patients at Risk', New Jersey Public Interest Research Group Law and Policy Center, 1-52
11. L. Chew T. O'Young T. Hazlet K. Bradley C. Maynard D. Lessler 2000 A Physician Survey of the Effect of Drug Sample Availability on Physicians' Behavior Journal of General Internal Medicine 15 478 483 10.1046/j.1525-1497. 2000.08014.x (Pubitemid 30640259)
12. P. Conrad 1992 Medicalization and Social Control Annual Review of Sociology 18 209 232 10.1146/annurev.so.18.080192.001233
13. P. Conrad 2005 The Shifting Engines of Medicalization Journal of Health and Social Behavior 46 3 14 (Pubitemid 41503889)
14. Conrad P.: (2007). The Medicalization of Society. Baltimore, MD: Johns Hopkins Press
15. P. Conrad V. Leiter 2004 Medicalization, Markets and Consumers Journal of Health and Social Behavior 45 Supplement 158 176
16. F. Davidoff B. Haynes D. Sackett R. Smith 1995 Evidence-Based Medicine: A New Journal to Help Doctors Identify the Information They Need British Medical Journal 310 1085 1086
17. J. Davis 2006 How Medicalization Lost Its Way Society 43 51 56 10.1007/BF02698486
18. Deshpande, R. and S. El-Chibini: 2005, 'Scientific Marketing Offers a New Way to Get Prescribers', Canadian Pharmaceutical Marketing (February), 37-38
19. Dhanda R.: (2002). Guiding Icarus: Merging Bioethics with Corporate Interests. New York: Wiley
20. Donohue J., M. Cevasco and M. Rosenthal: 2007, 'A Decade of Direct-to-Consumer Advertising of Prescription Drugs', New England Journal of Medicine 357(7), 673-681
21. Eaton M.: (2004). Ethics and the Business of Bioscience. Stanford, CA: Stanford University Press
22. M. Eaton 2008 Managing the Risks Associated with Using Biomedical Ethics Advice Journal of Business Ethics 77 99 109 10.1007/s10551-006-9296-x
23. Freidson E.: (1970). Profession of Medicine. New York: Dodd, Mead
24. J. Greene 2004 Attention to "Details": Etiquette and the Pharmaceutical Salesmen in Postwar, USA Social Studies of Science 34 271 292 10.1177/0306312704043029 (Pubitemid 38726849)
25. Gross A., P. Banting, L. Meredith, D. Ford: (1993). Business Marketing. Boston, MA: Houghton Mifflin Company
26. D. Healy 2004 Shaping the Intimate: Influences on the Experience of Everyday Nerves Social Studies of Science 34 219 245 10.1177/0306312704042620 (Pubitemid 38726847)
27. S. Heres J. Davis K. Maino E. Jetzinger W. Kissling S. Leucht 2004 Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics The American Journal of Psychiatry 194 185 194
28. D. Jones 2007 Health Authority Bans Physician Shadowing Canadian Medical Association Journal 177 1339 1340 10.1503/cmaj.071572
29. G. Jones R. Hagtvedt 2008 Marketing in Heterozygous Advantage Journal of Business Ethics 77 85 87 10.1007/s10551-006-9301-4
30. M. Lynch 2004 Ghost Writing and Other Matters Social Studies of Science 34 147 148 10.1177/0306312704044964 (Pubitemid 38726843)
31. McGee G.: (2003). Pragmatic Bioethics. Cambridge, MA: MIT Press
32. Meredith, L.: 2000, 'Strategic Choices for Business Marketers', in S. B. Dahiya (ed.), The Current State of Business Disciplines, Vol. 6: Marketing (Spellbound Publications, Rohtak, India), pp. 2909-2919
33. Moynihan R., A. Cassels: (2005). Selling Sickness: How the World's Biggest Pharmaceutical Companies are Turning Us All Into Patients. Vancouver: Greystone Books
34. O'Neil, P.: 2008, 'Ethics Guidelines for Clinical Trials to be Revised', Canadian Medical Association Journal 178(2), 138. doi: 10.1503/cmaj.071748
35. Parsons T.: (1951). The Social System. Glencoe, IL: Free Press
36. G. Poitras 1994 Shareholder Wealth Maximization, Business Ethics and Social Responsibility Journal of Business Ethics 13 125 134 10.1007/BF00881581
37. D. Radley S. Finkelstein R. Stafford 2006 Off-Label Prescribing Among Office Based Physicians Archives of Internal Medicine 166 1021 1026 10.1001/archinte.166.9.1021
38. Robbins-Roth C.: (2000). From Alchemy to IPO: The Business of Biotechnology. Cambridge, MA: Perseus
39. A. Schafer 2004 Biomedical Conflicts of Interest: A Defence of the Sequestration Thesis: Learning from the Cases of Nancy Olivieri and David Healy Journal of Medical Ethics 30 8 24 (Pubitemid 38262800)
40. S. Sismondo 2004 Pharmaceutical Maneuvers Social Studies of Science 34 149 159 10.1177/0306312704042575 (Pubitemid 38726844)
41. Steinman, M., L. Bero, M. Chren and S. Landefeld: 2006, Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents, Annals of Internal Medicine 145, 284-293
42. T. Szasz 1958 Psychiatry, Ethics, and the Criminal Law Columbia Law Review 58 February 183 198 10.2307/1119827
43. T. Szasz 1958 Scientific Method and Social Role in Medicine and Psychiatry A.M.A. Archives of Internal Medicine 101 February 228 238
44. Szasz T.: (1961). The Myth of Mental Illness. New York: Harper and Row
45. Thompson J., P. Baird, J. Downie: (2001). The Olivieri Report: The Complete Text of the Report of the Independent Inquiry Commissioned by the Canadian Association of University Teachers. Toronto: J. Lorimer
46. E. Turner A. Matthews E. Linardatos R. Tell R. Rosenthal 2008 Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy The New England Journal of Medicine 358 252 260 10.1056/NEJMsa065779
47. United States National Institutes of Health: 2008, 'ClinicalTrials.gov Website', http://clinicaltrials.gov/ct2/search/map
48. Wootton, B.: 1959, Social Science and Social Pathology (Assisted by V. G. Seal and R. Chambers) (Macmillan, New York)
49. I. Zola 1972 Medicine as a Institution of Social Control The Sociological Review 20 487 504